AAM Sees Extended Support For BIOSIM Act

Multiple US Organizations Come Together To Back Add-On Payment For Biosimilars

US representatives Kurt Schrader and Adam Kinzinger have introduced the BIOSIM Act to improve access and realize the full potential of biosimilars by encouraging an additional payment for providers when they use a biosimilar cheaper than the reference biologic. AAM and a group of organizations have extended support to the bipartisan bill. 

Support
AAM and a group of organizations have welcomed the BIOSIM Act • Source: Alamy

US representatives Kurt Schrader and Adam Kinzinger recently introduced the bipartisan Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act, garnering support from the Association for Accessible medicines and a group of organizations representing patients, employers, taxpayers, providers, communities of color and consumer groups. 

The AAM noted that “under Medicare Part B, health care providers are reimbursed the average sales price of the brand-name...

More from Biosimilars

More from Products